Close Menu

cancer screening

The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.

A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.

The health system said that the program is encouraging patient compliance and increasing revenues and savings.

Genetic testing results increasingly inform clinical decisions, though the inclusion of hereditary risk genes beyond BRCA1, BRCA2, and PALB2 sparked debate.

Data from more than 11,800 women with breast cancer suggested unselected BRCA1, BRCA2, and PALB2 testing is cost-effective for UK and US payors and societies.

The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.

Despite plenty of hype and some growing pains, artificial intelligence is starting to prove its value in academic and community cancer centers.

The company reported that its genome-wide methylation approach could detect 77 percent of stage II cancers in its ongoing case-control CCGA study.

Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.

After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.